SCHEMBL25139064

SCHEMBL25139064

CC(C)c1cc(-c2ccccc2C(N)=O)cc(C(C)C)c1CC(N)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCAT2 O15382 1/20 0.49
▸ HSP90AA1 P07900 2/20 0.39
▸ HSP90AB1 P08238 2/20 0.39
▸ CTSA P10619 5/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ ALOX5AP P20292 1/20 0.38
▸ FEN1 P39748 1/20 0.38
▸ NLRP3 Q96P20 1/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ KEAP1 Q14145 1/20 0.38
▸ NFE2L2 Q16236 1/20 0.38
▸ DPP4 P27487 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ PLA2G10 O15496 3/20 0.36
▸ PLA2G2A P14555 3/20 0.36
▸ PLA2G1B P04054 1/20 0.36
▸ PLA2G5 P39877 1/20 0.36
▸ PLA2G2C Q5R387 1/20 0.36
▸ PLA2G12B Q9BX93 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30010754 0.82 NLRP3 (0.39) HSP90AA1HSP90AB1NLRP3PLA2G2APLA2G1B
SCHEMBL25139030 0.81 HSP90AA1 (0.40) HSP90AA1HSP90AB1PLA2G2A
SCHEMBL25139048 0.79 NLRP3 (0.40) HSP90AA1HSP90AB1NLRP3PLA2G2A
SCHEMBL25139302 0.79 NLRP3 (0.46) HSP90AA1HSP90AB1NLRP3
SCHEMBL29493488 0.77 BCAT2 (0.53) BCAT2HSP90AA1HSP90AB1IRAK4KEAP1
SCHEMBL25138966 0.76 PTGER1 (0.51) HTT
SCHEMBL25138972 0.76 PTGER3 (0.43) —
SCHEMBL27926363 0.75 BCAT2 (0.76) BCAT2CHEK1ALOX5APFEN1KEAP1
SCHEMBL5490427 0.74 BCAT2 (0.51) BCAT2HSP90AA1HSP90AB1CTSACHEK1
SCHEMBL2817756 0.73 GABRA1 (0.55) HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3658538-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-04-19 — — EP disclosed
Send feedback